harvester schreef op 10 mei 2018 15:17:
MOR 106 in conference call Morphosys (transcript from 8 May Source Finance.yahoo:
The next compound from our Proprietary Development segment, where we have seen great progress, is MOR106. This potential first-in-class antibody targeting IL-17C is currently in co-development with Galapagos for the treatment of atopic dermatitis. In February of this year, we presented results of the AAD meeting in San Diego from our Phase I study of MOR106 in patients suffering from moderate-to-severe atopic dermatitis.
In the study, MOR106 was shown to be generally well tolerated and we saw first signs of clinical activity. Although efficacy was just an exploratory endpoint of the trial and treatment duration of 4 weeks was relatively short, at the highest dose level, 5 out of 6 patients reached an improvement of at least 50% of their atopic dermatitis symptoms, the so-called EASI-50 score. We also observed a durable effect of the antibody lasting for more than 2 months after the last administration of the antibody. Based on these Phase I findings, we have decided together with Galapagos to move the program into Phase II and just 2 days ago, we reported the enrollment of the first patient. The so-called IGUANA trial will evaluate 3 different intravenous doses of MOR106 and 2 different dosing schemes in 180 patients with moderate-to-severe atopic dermatitis over a 12-week treatment period.
This is an area of major unmet medical need in which we expect to be transformed by biologic therapies, in the way other inflammatory indications such as psoriasis have been transformed in the last 2 decades. We also see potential for MOR106 in other indications.